Lexeo Therapeutics, Inc. (LXEO), Thursday announced a research collaboration with Johnson & Johnson (JNJ) to investigate localized cardiac delivery of gene therapy.
Under the collaboration, the companies will seek to advance the potential efficacy and safety profile of gene therapy for genetically mediated cardiovascular diseases by concentrating AAV delivery to the heart by investigating cutting-edge routes of administration using Impella heart pump technology.
"We are thrilled to pair Lexeo's leadership in cardiac genetic medicine with Impella's world-class technology to advance a next generation of targeted genetic medicines for cardiovascular disease," CEO Nolan Townsend commented.
In the pre-market hours, LXEO is trading at $10.17, up 1.50 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.